WT1 and acute myeloid leukemia: In a prospective study conducted by Williams et al., expanded lymphocytes reactive to TAAs, including WT1, PRAME, and surviving, achieved 60% (3/5) CR rate in 5 AML patients relapsed after allo-HCT without causing GVHD (132).